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Abstract One of the hallmarks of glioblastoma is its
inherent tendency to recur. At this point patients with
relapsed GBM show a survival time of only few months.
The molecular basis of the recurrence process in GBM is
still poorly understood. The aim of the present study was to
investigatethe genetic proﬁle ofrelapsed GBM comparedto
theirrespectiveprimarytumors.Wehaveincluded20paired
GBMs. In all tumor samples, we have analyzed p53 and
PTENstatusbysequencinganalysis,EGFRampliﬁcationby
semiquantitative PCR and a wide-genome ﬁngerprinting
was performed by microsatellite analysis. Among primary
GBM, we observed twelve type 2 GBM, four type 1 GBM
and four further GBM showing neither p53 mutations nor
EGFR ampliﬁcation (non-type 1–non-type 2 GBM). Upon
recurrence, we have detected two molecular patterns of
tumor progression: GBM initially showing either type 1 or
type 2 proﬁles conserved them at the time of relapse. In
contrast, non-type 1–non-type 2 GBM acquired the typical
pattern of type 2 GBM and harbor EGFR ampliﬁcation
without p53 mutation. New PTEN mutations upon relapse
were only detected in type 2 GBM. Additional LOH were
more frequently identiﬁed in relapses of type 2 GBM than in
those showing the type 1 signature. Taken together, our
results strongly suggest that recurrences of GBM may
display two distinct pattern of accumulation of molecular
alterations depending on the proﬁle of the original tumor.




TTR Time to tumor relapse
MGMT O
6-methyl-guanine-methyl-transferase
CFTR Cystic ﬁbrosis transmembrane regulator
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Introduction
Glioblastoma multiforme is the most frequent primary
brain tumor in adults. One of its characteristic features is
the intrinsic tendency to recur despite aggressive therapy
[1]. Upon recurrence, the median survival of patients is
only few months [2] whereas the overall median survival
time is 15 months. This has not signiﬁcantly changed in the
last 20 years despite of advances in surgery, radio- und
chemotherapy [3, 4] A moderate improvement of the
2-year survival rate has been achieved after therapy with
the alkylating drug temozolomide in GBM with hyperme-
thylated MGMT compared to those with unmethylated gene
(46% vs. 26%) [3, 5, 6].
GBM is one of the most intensively investigated human
malignancy but the molecular mechanisms associated with
recurrence are still poorly understood. Saxena et al. [7]
reported a high rate of homozygous deletion of the genes
p16
INK4 and p15
INK4a in GBM relapses. In a further report,
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relapses and observed that recurrences displayed the pat-
tern of genetic alterations frequently observed in the de
novo pathway (GBM without a low grade precursor lesion)
[8]. Hulsebos et al. [9] analyzed 12 match paired GBM and
found in relapse cases new LOH at chromosome regions
1p36, 19q13, 10q23 and 1q25. In contrast to the former
study, GBM relapses encompassing new p53 mutation or
EGFR ampliﬁcation were not observed.
The identiﬁcation of molecular features associated with
recurrences of GBM is of major importance, since a better
understanding of this process might provide clues for the
development of efﬁcient treatments. In the present analysis,
we have examined the molecular signatures of forty tumors
consisting in relapsed GBM and their corresponding pri-
mary neoplasms which had undergone surgery and radio-
chemotherapy. This included the status of p53, PTEN and
EGFR as well as a wide genome LOH analysis with thir-
teen highly informative microsatellite markers at chromo-
some regions 17p13, 10q23, 1p35-36, 19q13, 13q14, 9p21.
Materials and methods
Patient population and tumor samples
All patients had undergone surgery with the goal of max-
imal possible tumor resection followed by fractionated
radiotherapy (mean dose: 58 Gray) and chemotherapy.
Forty paired tumors from twenty patients were available.
Informed consent for samples and data analysis from each
patient or the patient’s caretaker was obtained.
Tumor samples were immediately frozen in liquid
nitrogen after surgical resection and stored at -80C.
Tumor tissue was evaluated by experienced pathologists
according to the 2000 WHO classiﬁcation criteria. DNA
from tumor specimens was isolated applying the QIAamp

DNA Mini Kit (Qiagen, Hilden, Germany).
LOH analysis
LOH of chromosome 10q was studied with markers cov-
ering reported deletions on 10q23-24: D10S215, D10S541
and the intragenic PTEN marker PTENCA. Analysis of
LOH at 17p13 was performed with a p53 intragenic
localized marker. Allelic losses at 9p21 (p16
INK4a, p14
ARF
and p15) and 13q14 (RB1) were studied with primers
D9S171, D9S1748, D9S1749, D13S153 and D13S267.
Loss of heterozygosity at 1p35-p36 and 19q13 was asses-
sed with the markers D1S468, D1S482, D19S112 and
D19S412. Ampliﬁed PCR products were analyzed on a
denaturing 6.5% Long Ranger polyacrylamide gel on an
Automated Laser Fluorescence sequencing device and
analyzed using the ALLELELINKS
 1.00 software
(Amersham Pharmacia Biotech, Freiburg, Germany).
Evaluation of LOH was performed as described [10].
Semiquantitative PCR-analysis
For studying ampliﬁcation of EGFR a differential duplex-
PCR with the CFTR gene marker was carried out, as
described [11]. Brieﬂy, we calculated the EGFR/CFTR
ratios [x] from peripheral blood DNA of 20 healthy Cau-
casian adults. A value [x ? 3SD] was considered as the
cut-off level for the normal gene copy number. Ratios
higher than [x ? 3SD] were regarded as evidence of more
than 2 copies of the EGFR gene.
Sequencing analysis of p53 and PTEN
Mutational analysis of p53 and PTEN were performed in the
DNA frombothtumorsandcorresponding leukocytes.After
amplifying all exons and intron-exon boundaries, we ana-
lyzed the PCR products on 1% agarose gel and excised and
eluted them in sterile H2O. Subsequently, they were sub-
jected to cycle sequencing reactions using the Thermo
Sequenase
 Fluorescent Cycle Sequencing kit (Amersham
Pharmacia Biotech). The cycle sequencing products were
resolved using a denaturing 6.5% Long Ranger polyacryl-
amide gel on a sequencing device. PTEN primer sequences
and PCR conditions were previously described [12]. P53
primer sequences and PCR conditions are based on genome
database entries (http://www.ncbi.nlm.nih.gov). Brieﬂy,
PCR reactions were carried out using a mixture containing
150 ng DNA, 10 mM Tris, 2 mM MgCl2, HCl (pH 8.3),
0.2 mM dNTP, 10 mM concentrations of each primer and
0.5 unit of Taq DNA Polymerase. Temperature cycles and
times for PCR reactions were: denaturation at 94C for 30 s,
annealing at 65C for 30 s, and extension at 72C for 30 s.
Each PCR reaction was preceded by a 3-min denaturation at
94C, and the ﬁnal cycle was followed by a 3-min extension
at 72C. The total number of cycles for PCR ampliﬁcation
was 25–30, depending on the sample DNA.
Statistical analysis
Student t-test, Chi-square test, Fisher’s exact test and
Mann–Whitney U-test, were performed to compare dif-
ferences between groups depending on the analyzed vari-
ables. Spearman correlation test was used to evaluate the
correlation between two parameters. Conﬁdence interval
(CI) was obtained through logistic regression. Survival
studies were performed with the Kaplan Meier analysis and
the log-rank test. A value of P\0.05 was considered to be
signiﬁcant. Analyses were performed with the SPSS soft-
ware (version 10, SPSS Inc., Chicago, IL, USA).
322 J Neurooncol (2010) 96:321–329
123Results
Clinico-pathological characteristics of the patients
The male/female ratio was 1:1. The median age at diag-
nosis of primary tumor was 59.5 years (range: 27–69; SD:
12.25). The median time to tumor recurrence was
7.5 months (range: 3–24 months; SD: 5.1; 95%-CI: 5.3–
7.4 months). With one only exception, all patients dis-
played at diagnosis a Karnofsky performance score (KPS)
of [70 points. An association between age or KPS and
TTR was not evidenced (P = 0.35, q = 0.30, Spearman
correlation test). There were no signiﬁcant associations
between mutation of p53 or EGFR ampliﬁcation and either
survival time (P = 0.250 and 0.127, respectively, log-rank
test and Kaplan–Meier) or time to tumor relapse
(P = 0.210 and 0.287, respectively, log-rank test and
Kaplan–Meier).
Genetic analyses
In primary GBM we have observed EGFR ampliﬁcation
without mutations of p53 in 12 cases, thus indicating a type
II GBM proﬁle. Four further cases showed p53 mutations
(Table 1, Fig. 1) in the absence of EGFR ampliﬁcation,
which was indicative of a type 1 GBM signature. In four
Table 1 Sequence variations of p53 in type 1 glioblastomas
p53 sequence variations
Case Sequence variation Base exchange Aminoacid
substitution
CpG site Distribution
G3p c.278C[T CCT?TCT Pro?Ser No Somatic mutations in 74 tumors
Germline mut. in 2 Li-Fraumeni
a
c.266G[T GGA?GTA Gly?Val No Somatic mutations in 44 tumors
No germline mutations
a
G3r c.278C[T CCT?TCT Pro?Ser No Somatic mutations in 74 tumors
Germline mut. in 2 Li-Fraumeni
a
c.266G[T GGA?GTA Gly?Val No Somatic mutations in 44 tumors
No germline mutations
a
G7p c.72C[G (Arg72Pro) CCC?CGC Arg?Pro No Validated polymorphism
Higher risk lung cancer [34]
IVS3?21_37dup (P53PIN3) Validated polymorphism
Higher risk of CRC [36]
c.278C[T CCT?TCT Pro?Ser No Somatic mutations in 74 tumors
Germline mut. in 2 Li-Fraumeni
a
G7r c.72C[G (Arg72Pro) CCC?CGC Arg?Pro No Validated polymorphism
Higher risk lung cancer [34]
IVS3?21_37dup (P53PIN3) Validated polymorphism
aHigher risk of CRC [36]
c.278C[T CCT?TCT Pro?Ser No Somatic mutations in 74 tumors
Germline mut. in 2 Li-Fraumeni
a
G14p c.14G[C CTG?CTC Leu?Leu No Not described mutation
c.273G[A CGT?CAT Arg?His Yes Somatic mutations in 733 tumors
Germline mut. in 16 Li-Fraumeni
a
G14r c.14G[C CTG?CTC Leu?Leu No Not described mutation
c.273G[A CGT?CAT Arg?His Yes Somatic mutations in 733 tumors
Germline mut. in 16 Li-Fraumeni
a
G16p c.273G[A CGT?CAT Arg?His Yes Somatic mutations in 733 tumors
Germline mut. in 16 Li-Fraumeni
a
IVS2?38G[C Validated polymorphism [41]
G16r c.273G[A CGT?CAT Arg?His Yes Somatic mutations in 733 tumors
Germline mut. in 16 Li-Fraumeni
a
IVS2?38G[C Validated polymorphism [41]
a According to p53 data bases entries, mut mutation, CRC colorectal cancer
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123GBM neither p53 mutations nor EGFR ampliﬁcation were
identiﬁed (non-type 1–non-type 2 GBM).
At the time of recurrence, every type 1 GBM and type
2 GBM conserved their genetic pattern concerning p53
mutational status and EGFR ampliﬁcation. On the other
hand, relapses of non-type 1–non-type 2 GBM showed in
all cases a new EGFR ampliﬁcation, thus acquiring the
signature of type 2 GBM. Additional PTEN mutations in
relapse cases were observed only among type 2 GBM
(Table 2). Overall, additional LOH were observed more
frequently in relapses of type 2 GBM (83.3%), than in
those of type 1 (50%) or non-type 1–non-type 2 tumors
(25%). Further results are shown in Table 3.
Among p53 mutations there were one C:G to A:T
transition mutation at CpG site (codon 273), one C[T
transition at non-CpG site (codon 278), two transversion
mutations at non-CpG sites (G[C at codon 14 and G[Ta t
codon 266, Fig. 1) as well as one validated polymorphism
in exon 4 (G[C at codon 72). Moreover, we have
observed two validated intronic polymorphisms in intron 3
(IVS3?21_37dup) and intron 2 (IVS2?38G[C). One of
the mutations (c.14G[C) has not been previously described
in p53 data bases (http://www.p53.iarc.fr, http://www.p53.
free.fr). A detailed characterization of p53 sequence vari-
ations is shown in Table 1.
Concerning PTEN mutations, we have identiﬁed four
transition mutations in exons 2, 5, 6 and 7, in all cases
predicting aminoacid substitution. Furthermore, there was
an acceptor site splice mutation at the conserved junction
nucleotides (IVS8-2A[G). Finally, we have observed two
transversion mutations in exon 5 (c.105G[T) and exon 4
(c.75C[A, Fig. 2) as well as four intronic polymorphisms
(Table 2). The transition in exon 6 (c.177A[G), the
splicing mutation and two of the polymorphisms have not
been previously reported (Table 2).
The results of EGFR ampliﬁcation analysis and wide-
genome LOH are shown in Table 3 and Supplementary
Table 1 (EGFR/CFTR ratios). Interestingly, GBM cases
harboring mutations of p53 always displayed LOH at
17p13 as well. Similarly, tumors featuring PTEN mutations
showed LOH at 10q23, at least in one of the microsatellites
used to analyze this region.
Discussion
GBM mostly exceed in its occurrence and mortality
beyond any other primary brain tumor in adults [13]. On
molecular level, two subsets of GBM have been recognized
on the basis of genetic make-up and clinical features [14,
15]. Type 2 (de novo) GBM occurs commonly in elderly
patients and exhibit overexpression and/or ampliﬁcation of
EGFR. Type 1 (secondary) GBM shows typically histo-
logical progression from a previous low grade astrocytoma
and affects young patients. Paradigmatically, mutations of
p53 will be observed (for review see [15]). Most of GBM
cases belong to the type 2 group and genetic events are
mutually exclusive for EGFR and p53. Moreover, there are
GBM without either EGFR ampliﬁcation or p53 mutations
(non-type 1–non-type 2 GBM) [16, 17]. During the past
decade, accumulated evidence pointed to that type 1 and
type 2 GBM constitute distinct disease entities developing
through different genetic pathways [13, 14], showing dif-
ferent RNA and protein patterns [18, 19] and also probably
differing in response to treatment [15].
G T AA T C T A C T GGGA C GG AA C A G C T
Bases 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
G T AAT C T W C T GG T A C GGAAC A T C T
Bases 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Fig. 1 Upper row: wild type
sequence of p53. Lower row:
base exchange mutation
(GGA?GTA) of p53 (exon 8,
codon 266), predicting the
aminoacid substitution
Gly?Val. The arrow indicates
the base exchange
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Although this is a capital feature of GBM, only few
investigations with series of match paired patients are
available from the literature and available data is partially
contradictory [7–9, 20, 21]. We aimed to investigate
whether molecular subtypes of GBM also show different
proﬁles at the time of relapse.
In our genetic analysis, we have observed two patterns
of tumor recurrence (Fig. 3): GBM type 1 and type 2
retained upon recurrence their genetic alterations affecting
Table 2 Sequence variations of PTEN in ﬁrst and relapse glioblastomas
PTEN sequence variations
Case Sequence variation Mutation effect Aminoacid substitution Distribution
G1p c.44C[T GGC?GGT Gly?Gly Bladder cancer [39]
c.105G[T TGT?TTT Cys?Phe Gliomas [38]
G1r c.44C[T GGC?GGT Gly?Gly Bladder cancer [39]
c.105G[T TGT?TTT Cys?Phe Gliomas [38]
G2p c.177A[G TAT?TGT Tyr?Cys Not described mutation
IVS8?32G[T Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
G2r c.177A[G TAT?TGT Tyr?Cys Not described mutation
IVS8?32G[T Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
G4 c.105G[T TGT?TTT Cys?Phe Gliomas [38]
IVS8?32G[T Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
G4r c.105G[T TGT?TTT Cys?Phe Gliomas [38]
IVS8?32G[T Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
G5p IVS5-28_29ins C Not described polymorphism
IVS2-96A[G Not described polymorphism
G5r IVS5-28_29ins C Not described polymorphism
c.88A[G TAT?TGT Tyr?Cys Head neck squamous cell cancer [42]
G11p IVS5-28_29ins C Not described polymorphism
G11r IVS5-28_29ins C Not described polymorphism
c.88A[G TAT?TGT Tyr?Cys Head & neck squamous cell cancer [42]
IVS8-2A[G Splice mutation Not described mutation
G13p IVS5-28_29ins C Not described polymorphism
G13r IVS5-28_29ins C Not described polymorphism
IVS8-2A[G Splice mutation Not described mutation
c.75C[A CAT?AAT His?Asn Not described mutation
G17p IVS4 109_110 ins TCTTA Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
c.177A[G TAT?TGT Tyr?Cys Not described mutation
G17r IVS4 109_110 ins TCTTA Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
c.177A[G TAT?TGT Tyr?Cys Not described mutation
IVS5-28_29ins C Not described polymorphism
G19p IVS8?32G[T Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
G19r IVS8?32G[T Validated polymorphism
Cowden/Bannayan-Riley syndromes [40]
c.252A[G GAT?GGT Asp?Gly Glioma [43]
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type 2 GBM showed a new EGFR ampliﬁcation, thus they
acquired a type 2 GBM proﬁle. Accumulation of additional
genetic alterations upon relapse included PTEN mutations
in four type 2 GBM (but not in the other subtypes).
Additional LOH were more frequently observed in relapses
of type 2 GBM (in 10/12 cases) compared to relapses of
type 1 GBM and non-type 1–non-type 2 GBM (Table 3).
Table 3 Review of genetic changes of primary and relapsed glioblastomas






PTEN Loss of heterozygosity (LOH) 
1p35 9p21  13q14  19q13  10q23 17p13
G1p m 60  no  ther  3  n  y y
G1r m  60 no  ther      n  y y
G2p m 60  RT  6  n  n y    
G2r m  60  A,V      n  y y    
G3p f 62  RT  7  y  n n
G3r f  62  A,V      y  n n
G4p m 64  RT  3  n  y y
G4r m  64 no  ther      n  y y
G5p m 49  RT  9  n  y n
G5r m  49  A,V      n  y y
G6p f 57 RT/  A,V  10  n  n n             
G6r f  58  A,V      n  y n             
G7p f 31 no  ther  9  y  n n          
G7r f  32 RT/A,V     y  n n          
G8p m 39  RT  12  n  n n    
G8r m  40 no  ther      n  y n    
G9p m 69  RT/A,V 16  n  n n
G9r m  70  A,V      n  y n
G10p m  46  RT  17  n  y n       
G10r m  47  A,V      n  y n       
G11p m  37  RT  5  n  y n      
G11r m  38  no  ther      n  y y
G12p f  65  RT  6  n  y n            
G12r f  65  A,V      n  y n            
G13p f  55  RT  8  n  y n      
G13r  f  56  no ther     n  y y
G14p f  68  RT  9  y  n n             
G14r f  69  A,V      y  n n             
G15p f  64  RT  8  n  y n         
G15r  f  65  no ther     n  y n         
G16p f  27  RT  24  y  n n               
G16r f  29  T      y  n n               
G17p m  61  RT  8  n  y y      
G17r m  62  A,V      n  y y      
G18p f  59  RT/T  12  n  y n             
G18r f  60  T      n  y n       
G19p m  67  RT/T  9  n  y n          
G19r m  67  T      n  y y          
G20p f  58  RT/T  14  n  y n            
G20r f  59  T      n  y n            
TTR time to tumor relapse (months), Mut mutation, Ampl ampliﬁcation, p primary (ﬁrst tumor), r relapse (ﬁrst relapse), m male, f female, no ther
no adjuvant therapy performed, RT radiotherapy, A ACNU (nimustine), V VM26 (teniposide), T temozolomide. Black boxes loss of hetero-
zygosity, grey boxes retention of heterozygosity, white boxes not informative marker
* Age (years) at ﬁrst operation
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sion of transformed glial cells is well known in GBM,
confer tumor cells a growth advantage and underlies the
genetic heterogeneity of GBM [22, 23]. This phenomenon
contributes to explain the molecular differences between
primary tumors and relapses [9, 24, 25].
As a part of one previous investigation we had charac-
terized the promoter methylation status of the DNA repair
gene MGMT in all type 1 GBM (Table 3, cases G3, G7,
G14 and G16), non-type 1–non-type 2 GBM (Table 3,
cases G2, G6, G8 and G9) as well as eight type 2 GBM
here described [26]. This analysis together with the present
results of p53 and EGFR have evidenced similar rates of
MGMT methylation for the three GBM subtypes, and they
are in accordance with the overall methylation rates
reported in glioblastoma [5, 27]. Typically, MGMT was
methylated in the ﬁrst GBM and remained always meth-
ylated upon relapse. Thus, our results also conﬁrmed the
observation that, in the pathogenesis and progression of
GBM, MGMT becomes hypermethylated at an early stage
[28, 29] and remains methylated through progression, a
situation which was has been described in small adenomas
and carcinomas of colorectal origin as well [30]. The p53
mutational analysis in those type 1 GBM with methylated
MGMT showed G:C to A:T transition within CpG site
(c.273 CGT?CAT) in two cases. Further mutations of p53
in tumors with methylated MGMT (1 case) occurred in
non-CpG sites. From p53 data bases entries, approximately
52% of mutational events are transition mutations and, of
this subset, about 72% are G:C to A:T transitions (http://
www.p53.iarc.fr, http://www.p53.free.fr)[ 31], although the
signature of the mutational spectrum varies according to
T G T G C T G AAA G A C A TTA T G A C A CC G CCA
Bases 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87
T G T G C T G AAA G AA ATTA T G A M A CC G CC A
Bases 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88
Fig. 2 Upper row: wild type sequence of PTEN. Lower row: base exchange mutation (CAT?AAT) of PTEN (exon 4, codon 75) predicting the










Non type 1-non type 2 GBM









Fig. 3 Graphic showing two
molecular patterns of GBM
recurrence
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123tumor type. It was previously suggested a link [29] between
MGMT methylation and the presence of G:C to A:T tran-
sition mutations in p53 in gliomas. In the present study we
could conﬁrm the former in two patients (cases G14p, G14r,
G16p and G16r, Table 1); in these cases, G:C to A:T
transitions could be attributable to a inactivation in MGMT
that allows O
6-methylguanine to persist and be read as an
adenine. Our observations contrast with a recent investi-
gation about GBM reporting only 4% of mutations of p53 in
tumors with methylated MGMT within CpG sites [32]
although we should take in mind the size of our type 1 GBM
collective, clearly too short to state a deﬁnite tendency.
Strikingly, we have identiﬁed in cases G7p and G7r the
exonic p53 polymorphism c.72C[G (Arg72Pro) together
with the intronic polymorphism IVS3?21_37dup
(P53PIN3). Several investigations have pointed the asso-
ciation between p53 polymorphisms and an increased risk
for different cancers: for instance, in the case of the exonic
c.72 variant such association was suggested since the p53
protein with Arg72 is more efﬁcient in inducing apoptosis
than the one with the Pro72 variant [33]. In clinical studies,
the variants c.72 Pro/Pro and c.72 Arg/Pro have been
associated with an elevated risk of lung cancer [34, 35].
Recently, intron 3 duplication (IVS3?21_37dup) has been
found to be associated with increased risk of colorectal
cancer [36]. However, the authors could not determine
whether this intron 3 duplication alone inﬂuences mRNA
stability or if this effect requires the codon Pro72 variant.
To our knowledge, the occurrence of both polymorphisms
in GBM patients has not been reported before and pointed
to a possible role in brain cancer as well.
With respect to PTEN, we have identiﬁed mutations
only in type 2 GBM. In four cases, PTEN mutations
occurred in both the ﬁrst GBM and the relapse. In four
further cases, new mutations were observed in the recur-
rences but not in the ﬁrst tumor. The rate and pattern of
mutations are in accordance with previous reported data
[37]. All tumors with PTEN mutations also harbored LOH
at the chromosome region 10q23, which pointed to the
inactivation of this tumor suppressor gene and make patent
its contribution to the tumorigenesis and progression in
GBM.
Taken together, our results strongly suggest that GBM
relapses, compared to the corresponding ﬁrst tumor,
accumulate additional molecular alterations and may
develop along two distinct pathways, which contribute to
delineate the different proﬁles of type 1, type 2 and non-
type 1–non-type 2 GBM.
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